Description
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential.
The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19).
The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.
